Cancer-targeted pro-theranostic bi-metallic organo-coordination nanoparticles
Theranostics · 2025-01-01 · 15 (4) · 1205-1220
DOI: 10.7150/thno.99863 ↗At a glance
Journal article in Theranostics, published on 2025-01-01. Written by Hengbo Huang and 13 co-authors. Institution: Departments of Radiology, Washington University in St. Louis, MO 63110, USA. Major MEDLINE topics: Theranostic Nanomedicine, Nanoparticles. Cited 13 times so far (Crossref). The full text is freely available in PubMed Central. Funded by: NIBIB NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (original language)
Rationale
Cancer remains a leading cause of mortality, with aggressive, treatment-resistant tumors posing significant challenges. Current combination therapies and imaging approaches often fail due to disparate pharmacokinetics and difficulties correlating drug delivery with therapeutic response.
Methods
In this study, we developed radionuclide-activatable theranostic nanoparticles (NPs) comprising folate receptor-targeted bimetallic organo-nanoparticles (Gd-Ti-FA-TA NPs). Polyvalent tannic acid was used to coordinate titanium (Ti), a reactive oxygen species (ROS)-generating catalyst, gadolinium (Gd), a magnetic resonance imaging (MRI) contrast agent, and cypate, a near-infrared fluorescent dye.
Results
The NPs exhibited higher magnetic field-dependent relaxivities (r 1 = 20.8 mM⁻¹s⁻¹, r 2 = 72.1 mM⁻¹s⁻¹) than Gd-DTPA (r 1 = 4.8 mM⁻¹s⁻¹, r 2 = 4.9 mM⁻¹s⁻¹) on a 3 T MRI scanner. Tannic acid coordination reduced the Ti band gap from 3.3 eV in TiO₂ NPs to 2.0 eV, tripling ROS generation under UV light exposure. In breast cancer models (4T1 and PyMT-Bo1), Cerenkov radiating radiopharmaceuticals activated Gd-Ti-FA-TA NPs in vitro and in vivo, generating cytotoxic ROS to inhibit tumor cell viability and prevent tumor progression. In vivo, the NPs selectively accumulated in 4T1 tumors and enhanced both T1 and T2 MRI contrast, highlighting a strategy to locally activate cytotoxic ROS generation with radiopharmaceuticals for cancer treatment, utilizing cross-modality PET/MRI and optical imaging for shallow and deep tissue visualization.
Conclusion
The integrated nanoplatform allows direct imaging of drug delivery, providing guidance for the optimal timeline to activate therapeutic effects of pro-theranostic NPs via external triggers such as radionuclide-stimulated dynamic treatment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Departments of Radiology, Washington University in St. Louis, MO 63110, USA.
- Departments of Biomedical Engineering, Washington University in St. Louis, MO 63110, USA.
- Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Biomedical Engineering, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA.
Funding
- NIBIB NIH HHS
- NCI NIH HHS
- NIH HHS
Cite
APA
Huang, H., Fang, L., Wansapura, J., Prior, J. L., Manion, B., Xu, B., Hongsermeier, C., Gamadia, N., Blasi, N., Tang, R., Egbulefu, C., Shokeen, M., Quirk, J. D., & Achilefu, S. (2025). Cancer-targeted pro-theranostic bi-metallic organo-coordination nanoparticles. Theranostics, 15(4), 1205-1220. https://doi.org/10.7150/thno.99863
Vancouver
Huang H, Fang L, Wansapura J, Prior JL, Manion B, Xu B, et al. Cancer-targeted pro-theranostic bi-metallic organo-coordination nanoparticles. Theranostics. 2025;15(4):1205-1220. doi:10.7150/thno.99863
BibTeX
@article{Huang2025,
author = {Huang, Hengbo and Fang, Lei and Wansapura, Janaka and Prior, Julie L and Manion, Brad and Xu, Baogang and Hongsermeier, Cody and Gamadia, Nisha and Blasi, Nicole and Tang, Rui and Egbulefu, Christopher and Shokeen, Monica and Quirk, James D and Achilefu, Samuel},
title = {Cancer-targeted pro-theranostic bi-metallic organo-coordination nanoparticles},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {4},
pages = {1205--1220},
doi = {10.7150/thno.99863}
}
EUVIMED